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While inherited and acquired diseases
have proven invaluable in increasing
our understanding of the basement
membrane zone (BMZ), the identifica-
tion of the genes of various BMZ
proteins and the development of
advanced molecular techniques has
allowed for the development of many
new animal models, which present a
great opportunity for increasing our
knowledge of BMZ biology, the patho-
genesis of disease and ultimately the
treatment of these diseases.
Three types of animal models have
significantly advanced our understand-
ing of inherited diseases of the BMZ and
now provide in vivo paradigms to
further study their pathogenesis and to
test potential therapies. These animal
models include transgenic mice, immu-
nocompromised mice with transplanted
human skin equivalents and sponta-
neously occurring basement membrane
zone (BM) disease in large animals.
Distinct transgenic mouse models de-
monstrate many of the features of
inherited BM diseases, including the
simplex, junctional, hemidesmosomal
and dystrophic forms of epidermolysis
bullosa (EB). This was first established by
the Fuchs laboratory (Vassar et al.,
1991), who showed that transgenic mice
expressing a mutated form of keratin 14
demonstrated basal cell cytolysis and
intraepithelial blistering that mimicked
EB simplex to a remarkable degree. This
landmark study was the first to demon-
strate that a keratin gene mutation was
linked to an inherited disease in hu-
mans. Since that time, other transgenic
models have targeted a variety of BM
components to establish transgenic
models of hemidesmosomal (integrin-
a6, integrin-b4 and plectin), junctional
(laminin 5 subunits) and dystrophic
(type VII collagen) forms of EB.
Unfortunately, these transgenic
animals result in neonatal lethality that
has precluded long-term studies to test
therapeutic strategies targeted at pheno-
typic reversion of the BM defect. To
overcome this obstacle and to establish
humanized animal models of inherited
BM disorders, human skin equivalents
have been fabricated from primary cells
derived from EB patients and then
grafted to immunocompromised mice.
This novel approach was first used by
the Khavari laboratory (Ortiz-Urda
et al., 2003) to study the phenotypic
reversion of a skin equivalent generated
in vitro using keratinocytes from a
recessive dystrophic EB patient and then
transplanted to scid/scid mice. These
grafts were injected with an intradermal
bolus of recessive dystrophic EB fibro-
blasts that were engineered to correct
their type VII collagen deficiency
through overexpression of this protein.
Strikingly, this exogenous type VII col-
lagen was delivered to the BMZ and
resulted in the prevention of sub-epider-
mal blistering. Subsequently, a similar
animal model has been adapted by the
Woodley laboratory (Woodley et al.,
2004) to correct a recessive dystrophic
EB phenotype by direct injection of a
recombinant form of human type VII
collagen. The successful reversion of
this disease phenotype supports future
use of protein-based therapy to treat
inherited skin disorders of BM.
Finally, spontaneously occurring,
large animal models of inherited BM
disease have been well characterized
and are now available to study these
diseases in an immunocompetent back-
ground. These naturally occurring dis-
eases mimic the simplex (bovine),
hemidesmosomal (dog), junctional
(horse, dog) and dystrophic (sheep,
dog, cat) forms of EB and have been
linked to the characteristic genotypes
and phenotypes seen in their human
counterparts (Spirito et al., 2002; Capt
et al., 2005; Hengge, 2005). Interest-
ingly, phenotypes observed in these
animals demonstrate varying degrees of
severity that have been linked to levels
of functional BM proteins. For exam-
ple, a breed of German Pointer man-
ifests an intronic mutation in the gene
encoding the a3 chain of laminin 5
that interferes with RNA maturation,
decreases levels of functional laminin 5
and results in a mild phenotype similar
to that seen in non-Herlitz junctional
EB. In contrast, a horse model that
mimics severe Herlitz junctional EB has
been linked to a base pair insertion
generating a premature termination
codon that leads to complete loss of
laminin-a2 expression. These large
animal models provide new opportu-
nities to test delivery of therapeutic
genes or gene products to correct
molecular defects underlying these
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conditions, while testing host immuno-
tolerance. All of these animal models
now play a critical role in validating
discoveries made in vitro, in an in vivo
context, to help close the loop between
basic scientific investigation of inheri-
ted BM disease and translational
discovery paradigms that will lead to
the amelioration of these disease con-
ditions (Jiang and Uitto, 2005).
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